Achieve Therapy Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 403 Briggs Ave S, Park River, ND 58270 Phone: 701-284-6707 |
Benjamin Phelps, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 115 Vivian St W, Park River, ND 58270 Phone: 701-284-4570 |
Joseph J Karas Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 115 Vivian St W, Park River, ND 58270 Phone: 701-284-7500 |
Lyndsi E Klundt, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 403 Briggs Ave S, Park River, ND 58270 Phone: 701-284-6707 |
Corissa Rae Kruse Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 115 Vivian St W, Park River, ND 58270 Phone: 701-284-4570 Fax: 701-284-4581 |
Raevyn Haugland Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 115 Vivian St W, Park River, ND 58270 Phone: 701-284-4682 Fax: 701-284-4581 |
News Archive
Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.
In response to the yellow fever outbreak currently on-going in Brazil some 3.5 million doses of vaccine from the emergency stockpile were deployed to the country through the International Coordinating Group (ICG) on Vaccine Provision for yellow fever.
Food presented in a virtual reality environment causes the same emotional responses as real food. Researchers writing in BioMed Central's open access journal Annals of General Psychiatry compared the responses of people with anorexia and bulimia, and a control group, to the virtual and real-life snacks, suggesting that virtual food can be used for the evaluation and treatment of eating disorders.
Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.
The development of effective preventive and therapeutic measures to control eating and body weight involves basic physiology as well as cognitive and social psychology.
› Verified 5 days ago